Lumida
/TBPH
⌘K
Theravance Biopharma Inc

Theravance Biopharma Inc

TBPH
$17.01USD-0.06%-0.01 today

MARKET CAP

883.1M

P/E (TTM)

67.0x

FWD P/E

6.6x

DAY RANGE

$17 – $17

52W RANGE

$13
$21

AI Summary

Stalk
Buy NowMedium

TBPH is exhibiting signs of structural repair with a Bullish Pivot Point pattern and price holding above key short-term EMAs. The intermediate trend is supported by mean-reversion dynamics, while the long-term uptrend remains intact. EMAs are flattening and turning higher, and RSI and Options Score show no exhaustion. The momentum-focused strategy favors participation on shallow pullbacks into rising EMA support.

  • Q1 2026 revenue of $17.7M (+15% YoY) driven by YUPELRI partnership
  • ROE at 50% with high earnings yield underscores strong profitability
  • Analysts’ downward revisions highlight weakening earnings outlook
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$55.3M$51.3M$57.4M$64.4M$107.5M
YoY %-23.0%-7.2%+11.8%+12.1%+66.9%
P / Sales13.9x15.7x11.2x7.1x9.0x
EV / Sales25.1x13.1x13.4x9.3x9.2x
Gross Profit, Adj.$55.3M$51.3M$57.4M$64.4M$107.5M
YoY %-23.0%-7.2%+11.8%+12.1%+66.9%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit25.1x13.1x13.4x9.3x9.2x
EBITDA, Adj.$-237.6M$-71.4M$-51.3M$-40.7M$-2.0M
YoY %+20.2%+69.9%+28.2%+20.6%+95.1%
Margin %-429.6%-139.1%-89.3%-63.3%-1.8%
EV / EBITDA-5.9x-9.4x-15.0x-14.7x-498.3x
EBIT$-257.8M$-92.0M$-56.0M$-46.9M$-3.6M
YoY %+13.4%+64.3%+39.1%+16.2%+92.3%
Margin %-466.1%-179.1%-97.6%-72.9%-3.4%
EV / EBIT-5.4x-7.3x-13.7x-12.8x-273.4x
Net Income$-199.4M$872.1M$-55.2M$-56.4M$105.9M
YoY %+28.3%+537.3%-106.3%-2.2%+287.7%
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (GAAP)-$2.87$11.85-$1.00-$1.15$2.06
YoY %+35.7%+512.9%-108.4%-15.0%+279.1%